Massachusetts IP lawyer wins honors for patent strategy

Patent lawyer David Dykeman is co-chair of Greenberg Traurig’s global Life Sciences & Medical Technology Group. [Photo courtesy of Greenberg Traurig]

Greenberg Traurig patent attorney David Dykeman has been recognized as “Patent Strategy Attorney of the Year – Massachusetts” by LMG Life Sciences.

Dykeman is co-chair of the law firm’s global Life Sciences & Medical Technology Group, co-managing shareholder of the firm’s Boston office, and the founding co-chair of the American Bar Association’s Medical Devices Committee. His practice focuses on securing worldwide intellectual property protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, robotics, materials and information technology, the law firm said.

RELATED: How IP protection is enabling robotic surgery innovation

“Massachusetts is one of the thriving hubs for …

Read more
  • 0

Moderna says Pfizer-BioNTech COVID vaccine infringed its patents

Moderna (Nasdaq:MRNA) announced today that it is suing Pfizer and its COVID-19 vaccine partner BioNTech over patent infringement in U.S. and German courts.

Cambridge, Massachusetts–based Moderna said it is in the process of filing the complaints in U.S. District Court in Massachusetts and the Regional Court of Düsseldorf in Germany.

The suits could pit three of the most significant COVID-19 vaccine makers against each other in an IP battle with billions of dollars potentially at stake. COVID-19 vaccine revenue boosted Pfizer to the top of the list among the Pharma 50 largest pharmaceutical companies on Drug Discovery & Development. Moderna and BioNTech also joined the Pharma 50 for the first time in the most recent edition.

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,” Moderna CEO…

Read more
  • 0

How the LOT Network seeks to protect medtech, biopharma IP

There are about 30,000 to 40,000 patents for sale on the open market at any moment. Traditionally, most patents for sale stem from distressed tech companies.

Patent assertion entities (PAEs, sometimes referred to as “patent trolls”) take advantage of the situation by buying up patents that provide fodder for patent lawsuits.

“They can just find a halfway decent looking patent for $50,000 or $100,000, and then they can threaten a high tech company with a $100 million lawsuit,” said Ken Seddon, CEO of the nonprofit LOT Network focused on protecting companies from the threat of PAE litigation.

Get the full story form our sister site, Drug Discovery & Development. 

Read more
  • 0